https://doi.org/10.46344/JBINO.2025.v14i04.11

BEYOND BIOLOGY: EXPLORING HOW GENDER INFLUENCES SICKLE CELL DISEASE OUTCOMES AND CARE

Emmanuel Ifeanyi Obeagu

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

Email : emmanuelobeagu@yahoo.com

ABSTRACT

Sickle Cell Disease (SCD) is a genetic blood disorder characterized by severe pain, anemia, and a range of other complications. Recent research has identified potential gender differences in disease manifestation, severity, and management.This review aims to investigate the gender-based differences in Sickle Cell Disease outcomes, including variations in disease severity, pain management, and healthcare access.A comprehensive literature review was conducted, analyzing peer-reviewed studies, clinical trials, and health reports on gender differences in SCD. The review focused on clinical manifestations, pain management strategies, and healthcare access issues, synthesizing findings to highlight disparities between male and female patients.The review found significant gender differences in Sickle Cell Disease outcomes. Women with SCD often experience different pain patterns and may report more severe pain, yet their pain is sometimes underestimated. Men, on the other hand, may face earlier onset and higher severity of complications such as stroke and acute chest syndrome. Gender disparities in healthcare access and utilization were also observed, with women facing additional barriers. These differences suggest a need for gender-specific approaches in treatment and care.Gender differences in Sickle Cell Disease affect disease severity, pain management, and healthcare access, underscoring the need for tailored treatment strategies. Personalized approaches that consider gender-specific factors can improve patient outcomes and ensure more equitable care.

Keywords: *Sickle Cell Disease, Gender-Based Disparities, Patient Outcomes, Clinical Presentation, Anemia*

Introduction

SCD is a genetic disorder caused by a mutation in the β-globin gene, resulting in the production of abnormal hemoglobin known as hemoglobin S.[1] This genetic defect causes red blood cells to adopt a characteristic sickle shape under low-oxygen conditions, which leads to chronic pain, anemia, and various serious health complications. Despite significant progress in the management and treatment of SCD, including the development of new therapies and advancements in understanding the disease's pathophysiology, there remains a substantial gap in addressing gender-based disparities in patient outcomes.[2-4] Historically, research into SCD has often focused on the disease's biological mechanisms and treatment efficacy without fully considering how gender differences may influence disease progression and management.[5] However, emerging evidence suggests that males and females experience the disease in distinct ways, from the frequency and severity of vaso-occlusive crises to variations in treatment responses and overall health outcomes.[6]One of the most significant aspects of SCD is the occurrence of vaso-occlusive crises, which are painful episodes resulting from the obstruction of blood flow in small blood vessels.[7] Research has shown that there may be gender differences in the frequency and severity of these crises.[8] For example, some studies suggest that females may experience more frequent and intense pain episodes compared to their male counterparts. These differences might be related to hormonal fluctuations, which can exacerbate symptoms or trigger pain episodes. Examining these disparities can provide insight into the biological and physiological factors that influence the clinical presentation of SCD.In addition to differences in crisis frequency, the management of SCD often involves medications such as hydroxyurea, which aims to reduce pain crises and improve patient outcomes. However, there is evidence to suggest that males and females may respond differently to hydroxyurea treatment. For instance, some studies have reported that females might experience different side effects or varying levels of efficacy compared to males.[9] These differences in treatment response highlight the need for gender-specific treatment protocols and underscore the importance of exploring how gender influences medication effectiveness and patient adherence.

Gender disparities also extend to the quality of life for individuals with SCD. Quality of life is a multifaceted concept encompassing physical, emotional, and social well-being. Research indicates that females with SCD may report lower quality of life scores compared to males. This disparity can be attributed to various psychosocial factors, including the impact of chronic pain on daily life, differences in coping strategies, and the availability of social support. By understanding these factors, healthcare providers can develop

strategies to address the unique challenges faced by female patients.[10-11] Furthermore, gender-based disparities in SCD management may also be influenced by socio-economic factors and access to healthcare.[12] Women with SCD might face more barriers to accessing appropriate medical care due to economic challenges, differences in health insurance coverage, or systemic gender biases in healthcare settings. These socio-economic and systemic issues can affect the quality of care received and contribute to unequal health outcomes between genders.Another important aspect to consider is the role of hormonal changes throughout a patient's life, including during menstruation, pregnancy, and menopause. Hormonal fluctuations can significantly impact the severity of SCD symptoms and the effectiveness of treatments.[13] For example, the menstrual cycle and pregnancy can influence pain management and the risk of complications, which may differ between genders. Research into these hormonal influences can help tailor treatments to better meet the needs of female patients.The need for gender-sensitive research and interventions in SCD is becoming increasingly apparent.[14] To address these disparities, future research must not only document differences in outcomes but also investigate their underlying causes. This includes exploring how hormonal changes affect disease progression, developing gender-specific treatment guidelines, and addressing socio-economic barriers to care. Such research will be crucial for creating equitable treatment strategies and improving outcomes for all SCD patients.

Aim

The aim of this review is to provide a comprehensive overview of the gender-based disparities in patient outcomes related to SCD and to outline future research priorities and directions for advancing the management and understanding of the disease.

Rationale

The rationale for this review stems from the recognition that SCD presents unique challenges for patients, which can be significantly influenced by gender. Despite advances in treatment and understanding of SCD, gender-based differences in disease outcomes, treatment responses, and psychosocial factors remain underexplored and under-addressed. This review seeks to fill this gap by highlighting these disparities and proposing future research directions to improve SCD management. SCD affects both men and women, but emerging evidence suggests that gender plays a crucial role in determining disease outcomes. Research indicates that males and females may experience different disease manifestations and complications. For example, males might face a higher risk of severe pain crises, while females might experience more significant challenges related to reproductive health and disease management. Understanding these gender-based disparities is essential for developing tailored interventions that address the specific needs of both male and female patients. Despite advancements in SCD therapies, there are still significant disparities in treatment

access and effectiveness between genders. For example, women may face unique barriers related to treatment adherence, such as balancing disease management with family responsibilities. On the other hand, men might experience different forms of stigma or challenges in accessing care. By examining these disparities, the review aims to highlight gaps in current treatment strategies and propose gender-specific interventions to enhance care for all patients.

SCD has profound psychosocial impacts that vary between genders. Women and men may experience different levels of psychological stress, stigma, and support needs. For instance, women might face challenges related to pregnancy and reproductive health, while men may experience issues related to stigma and societal expectations. Understanding these psychosocial factors is essential for developing support mechanisms that improve the quality of life for SCD patients. Health inequities in SCD care are a significant concern, with differences in access to care, treatment quality, and health outcomes based on gender, socioeconomic status, and geographic location. Women may face additional barriers related to health insurance coverage and access to specialized care. This review seeks to uncover these inequities and propose measures to ensure that all patients receive the care they need, regardless of gender. There is a need for ongoing research to address the complex and evolving challenges of SCD. Future research should explore novel therapies, innovative treatment approaches, and advanced technologies that could transform SCD care. By identifying research gaps and proposing new areas for investigation, this review aims to drive future advancements in SCD management.

Epidemiology of Sickle Cell Anemia Based on Gender

Sickle cell anemia, a severe form of SCD, is a genetic blood disorder characterized by the production of hemoglobin S, which distorts red blood cells into a sickle shape. These sickle-shaped cells can cause blockages in blood vessels, leading to pain, anemia, and a host of other health complications. While sickle cell anemia affects both males and females, there is a growing body of evidence that suggests the disease's epidemiology is influenced by gender, resulting in distinct patterns in disease incidence, clinical outcomes, and management between men and women.[15-17] Globally, sickle cell anemia affects millions of individuals, with the highest prevalence observed in sub-Saharan Africa, parts of India, and the Middle East.[18] The incidence of SCD is roughly equal between genders at birth, as the genetic mutation causing the disease is inherited equally from both parents. However, the gender distribution of the disease often shifts when examining clinical outcomes and disease severity. Studies indicate that while the prevalence of sickle cell anemia at birth is approximately the same for both sexes, the manifestation and progression of the disease can differ between males and females over the course of a lifetime.The clinical manifestations of sickle cell anemia are marked by episodes of severe pain known as vaso-occlusive crises, anemia, and

potential complications such as acute chest syndrome and stroke.[19] Research shows that females might experience more frequent and severe vaso-occlusive crises compared to males.[20] For example, a study conducted in a large cohort of SCD patients found that women reported higher levels of pain and a greater number of pain crises than their male counterparts. One potential explanation for this disparity is the influence of hormonal changes, such as those occurring during menstruation or pregnancy, which can exacerbate pain and lead to increased disease complications for females.

In addition to differences in pain episodes, the progression of sickle cell anemia and the incidence of related complications also appear to differ by gender. Females with SCD are often at a higher risk for certain complications, such as acute chest syndrome and stroke, compared to males.[21] Some studies suggest that this increased risk may be linked to hormonal fluctuations and the impact of reproductive health on disease severity.[22] For example, hormonal changes associated with menstruation, pregnancy, and menopause can influence disease activity, with many female patients experiencing worsened symptoms during these periods.When it comes to treatment, the response to therapies such as hydroxyurea—a medication used to reduce the frequency of pain crises and other complications—can vary between genders. Clinical trials and observational studies have reported that females might have different responses to hydroxyurea treatment compared to males, including variations in the medication's effectiveness and side effects. These differences highlight the importance of considering gender when developing and administering treatment regimens. For instance, some research has suggested that females may require different dosing strategies or additional supportive therapies to achieve optimal outcomes.The quality of life for individuals with sickle cell anemia is significantly impacted by the disease's chronic nature and associated complications. Studies show that females with SCD often report a lower quality of life compared to males.[23-24] This difference is not solely due to the physical manifestations of the disease but also reflects psychosocial factors such as stress, coping mechanisms, and social support. Women may face unique challenges in managing their health, including balancing the demands of SCD with other responsibilities such as work and family life, which can further affect their overall well-being.

Gender-based socio-economic barriers also play a role in the epidemiology of sickle cell anemia. Women with SCD may face additional hurdles in accessing healthcare resources compared to men.[25] These barriers include differences in health insurance coverage, economic instability, and potential gender biases in healthcare settings. For example, women might experience difficulties in securing adequate health insurance coverage or accessing necessary treatments, which can lead to delays in care and poorer health outcomes.Hormonal influences are a significant factor in the gender-based differences observed in sickle cell anemia. Research has shown that female patients

may experience fluctuations in disease severity in relation to hormonal changes during the menstrual cycle, pregnancy, and menopause.[26] These hormonal changes can impact the frequency and intensity of pain crises, as well as the overall management of the disease. Understanding these influences is crucial for developing gender-specific management strategies that address the unique needs of female patients. In terms of long-term health outcomes, there is evidence to suggest that survival rates for individuals with sickle cell anemia may differ between genders. While survival rates have improved for both males and females due to advancements in treatment, some studies have reported that females might face a greater risk of mortality from certain SCD-related complications.

Gender-Based Biological Variations

Sickle cell anemia, a form of SCD characterized by the presence of hemoglobin S, manifests differently in males and females due to a variety of biological factors. These gender-based biological variations influence disease progression, clinical manifestations, treatment responses, and overall health outcomes.One of the most significant biological differences between male and female patients with sickle cell anemia is the impact of hormonal fluctuations.[27] Hormones such as estrogen and progesterone, which vary across the menstrual cycle, pregnancy, and menopause, have been shown to influence the severity of sickle cell symptoms. For instance, research has demonstrated that the hormonal changes associated with the menstrual cycle can exacerbate the frequency and intensity of vaso-occlusive crises in females. Similarly, during pregnancy, increased blood volume and hormonal changes can impact disease severity and complicate management strategies for female patients.Gender differences in pain perception are another important factor in sickle cell anemia. Studies have shown that females may experience higher levels of pain during vaso-occlusive crises compared to males.[28-29] This variation in pain perception might be attributed to both physiological and psychological factors. For example, hormonal fluctuations can influence pain sensitivity, and psychosocial factors such as stress and coping mechanisms may also contribute to the gender differences observed in pain experiences.

Genetic and epigenetic factors also contribute to gender-based variations in sickle cell anemia.[30] While the mutation causing sickle cell anemia is inherited equally from both parents, there are gender-specific genetic and epigenetic mechanisms that can influence disease outcomes. For example, some research suggests that females may have different patterns of gene expression related to inflammation and pain compared to males. These differences can affect how the disease progresses and responds to treatment. Additionally, the X chromosome, which has varying gene expression patterns between males and females, may also play a role in these variations.The immune system's response to sickle cell anemia can vary between genders.[31] Females may have different

immune responses compared to males, which can influence disease severity and complication rates. For instance, females might have a more pronounced inflammatory response, which can exacerbate symptoms of sickle cell anemia and lead to more frequent complications such as acute chest syndrome. The pathophysiology of red blood cells in sickle cell anemia also differs between genders.[32] Female patients might experience more significant anemia compared to males, potentially due to differences in red blood cell production and destruction. Additionally, hormonal changes that affect blood volume and cell turnover can lead to variations in the severity of anemia and other blood-related complications. Exploring these blood cell pathophysiological differences can provide insights into how gender impacts disease management.

Responses to treatment for sickle cell anemia can also be influenced by gender.[33] For example, females may experience different efficacy and side effects from treatments such as hydroxyurea compared to males. Hydroxyurea, a medication used to reduce pain crises and other complications, may have varying effects due to differences in drug metabolism, hormonal influences, and genetic factors. Additionally, side effects of treatments can differ between genders, necessitating gender-specific approaches to therapy.Gender-based variations in bone marrow function and hematopoiesis, the process of blood cell production, may also affect sickle cell anemia.[34] Differences in bone marrow response to stress, infection, and other stimuli can influence disease progression and treatment outcomes. For instance, females might experience different patterns of hematopoietic stem cell activity compared to males, which can impact the management of sickle cell anemia.Vascular complications, such as stroke and priapism, exhibit gender-based differences in sickle cell anemia.[35] Males are generally at a higher risk for certain vascular complications like priapism, while females may experience different patterns of vascular damage and stroke risk. Reproductive health significantly impacts the management of sickle cell anemia in females.[36] The challenges of managing sickle cell anemia during pregnancy and the influence of reproductive health on disease severity are important considerations. Female patients with sickle cell anemia may face unique challenges related to reproductive health, including higher risks of pregnancy-related complications and considerations for family planning and pregnancy management.

Clinical Manifestations and Disease Progression

Sickle cell anemia, a genetic disorder caused by mutations in the β-globin gene, leads to the production of sickle-shaped red blood cells that cause various clinical manifestations and disease complications.[37] While both males and females are affected by sickle cell anemia, there are notable gender-based differences in how the disease manifests and progresses over time. Vaso-occlusive crises are one of the hallmark symptoms of sickle cell anemia, characterized by acute episodes of severe pain caused by the

obstruction of blood flow in small blood vessels.[38] Research indicates that females with sickle cell anemia often experience more frequent and severe vaso-occlusive crises compared to males.[39] This increased frequency of pain crises in females may be influenced by hormonal fluctuations, such as those occurring during the menstrual cycle or pregnancy, which can exacerbate the pain and increase the risk of crisis episodes. A study found that female patients reported significantly higher levels of pain and a greater number of vaso-occlusive crises compared to male patients, especially during menstruation and pregnancy periods.Acute chest syndrome (ACS) is a serious complication of sickle cell anemia that presents with chest pain, fever, and respiratory symptoms.[40] ACS is a leading cause of hospitalization and mortality in SCD patients. Research suggests that females may have a higher risk of developing ACS compared to males.[41] The increased incidence of ACS in females might be due to both hormonal influences and differences in immune responses, which can affect the inflammatory processes associated with this condition. A study demonstrated that female patients with sickle cell anemia had a higher incidence of ACS and related complications, which could be linked to increased inflammation and respiratory complications.

Anemia is a persistent feature of sickle cell anemia, caused by the destruction of sickle-shaped red blood cells.[42] Females with sickle cell anemia may experience more severe anemia compared to males, which can be exacerbated by menstrual blood loss and pregnancy-related changes. Hematologic complications such as splenic sequestration and acute anemia are also observed, with females potentially facing different patterns of these complications due to physiological and hormonal factors. Research has shown that females with sickle cell anemia are at increased risk for severe anemia and related complications, potentially due to menstrual blood loss and other hormonal factors.Stroke is a serious complication of sickle cell anemia, with patients at risk for both ischemic and hemorrhagic strokes. Studies have indicated that males with sickle cell anemia are at a higher risk of stroke compared to females, which may be related to gender differences in blood flow dynamics and vascular health.[43] However, females are also at risk, especially during periods of increased disease activity or hormonal changes that could influence stroke risk. A review of clinical data found that males with sickle cell anemia had a higher incidence of stroke compared to females, although both genders remain at significant risk for this serious complication.

Priapism, a painful and prolonged erection unrelated to sexual desire, is a condition more commonly observed in males with sickle cell anemia.[44] It occurs due to the obstruction of blood flow in the penile vasculature and can lead to long-term damage if not treated promptly. Females, on the other hand, do not experience priapism, highlighting a key gender difference in clinical manifestations of sickle cell anemia. Research indicates that priapism is a frequent complication in male patients with sickle cell anemia, affecting about 30% of males with the

disease.Chronic pain and osteonecrosis (bone damage due to interrupted blood flow) are common in sickle cell anemia. Studies suggest that females may experience more chronic pain and a higher incidence of osteonecrosis compared to males.[45] The increased risk of chronic pain in females might be related to both biological and psychosocial factors, including hormonal influences and coping mechanisms. A study revealed that females with sickle cell anemia reported higher levels of chronic pain and a greater incidence of osteonecrosis compared to males.[46] Reproductive health issues are significant for female patients with sickle cell anemia.[47] Complications related to pregnancy, such as preeclampsia, preterm labor, and increased risk of maternal and fetal morbidity, are of particular concern. Hormonal changes during pregnancy and reproductive health issues require careful management to minimize risks for both mother and child. Females with sickle cell anemia face increased risks during pregnancy, including complications such as preeclampsia and preterm labor.

The spleen plays a crucial role in filtering blood and fighting infections, but in sickle cell anemia, it can become damaged or sequester red blood cells.[48] While both genders are at risk for splenic complications, females might experience these issues differently due to hormonal factors and increased disease activity during specific life stages. Studies have shown that females may experience more severe splenic complications compared to males, which can be related to hormonal influences and disease severity.Children with sickle cell anemia may face growth and development issues, and there is evidence suggesting that these issues may differ between boys and girls.[49] Girls may experience delayed growth or puberty compared to boys, potentially due to the chronic nature of the disease and its impacts on overall health. Research has documented that girls with sickle cell anemia may experience delayed growth and puberty compared to boys, influenced by the chronic effects of the disease.The psychosocial impacts of sickle cell anemia, including mental health issues such as depression and anxiety, can also differ by gender.[50] Females with sickle cell anemia may report higher levels of psychological distress compared to males, influenced by disease-related pain, social support networks, and coping strategies. A study found that females with sickle cell anemia reported higher levels of depression and anxiety, which could be related to the stress of managing chronic disease and seeking support.

Socioeconomic and Psychosocial Determinants

The impact of sickle cell anemia extends beyond the realms of biology and clinical manifestations, reaching into the intricate web of socioeconomic and psychosocial determinants.[21] Socioeconomic disparities can significantly influence access to healthcare resources, affecting the frequency and quality of medical interventions for individuals with sickle cell anemia. Gender-specific considerations may arise, impacting reproductive health services, family planning, and access to specialized care. Disparities in the quality of healthcare services, including access to hematologists, pain management

specialists, and comprehensive care centers, can contribute to variations in disease management outcomes. Socioeconomic factors may intersect with gender-specific health needs, influencing the overall quality of care provided. The availability of health insurance and its affordability are critical determinants of access to essential medical services and medications. Socioeconomic factors, including income disparities and employment opportunities, may intersect with gender-based considerations, influencing insurance coverage and financial barriers to care.

Educational attainment and employment opportunities can be influenced by the impact of sickle cell anemia on academic performance and the ability to maintain consistent employment.[52] Gender-specific factors may play a role, affecting career choices, workplace accommodations, and family planning decisions. Stigmatization associated with sickle cell anemia can have profound psychosocial effects on individuals, impacting self-esteem, social relationships, and mental well-being.[53] Gender-specific stigma may intersect with societal expectations and norms, influencing coping mechanisms and mental health outcomes. The level of family and social support is a crucial determinant of the overall well-being of individuals with sickle cell anemia. Socioeconomic factors may influence the availability of support networks, and gender-specific roles and expectations within families can shape the nature of this support. Reproductive health decisions, including family planning, may be influenced by the unique considerations of living with sickle cell anemia. Gender-specific factors, such as the impact of the disease on fertility and pregnancy outcomes, can shape reproductive choices and family planning decisions. The availability of community resources, support groups, and advocacy initiatives can play a pivotal role in enhancing the overall quality of life for individuals with sickle cell anemia. Socioeconomic factors may influence access to these resources, and gender-specific considerations may shape the nature of community support and advocacy efforts.Tailoring interventions to account for the intersectionality of these factors, including gender-specific considerations, is crucial for promoting equitable access to care, improving overall quality of life, and addressing the broader societal challenges associated with this complex hematological disorder. Continued research and advocacy efforts are essential to mitigate the impact of socio-economic and psychosocial determinants on individuals living with sickle cell anemia.

Clinical Presentation of Sickle Cell Disease Based on Gender

SCD is a genetic disorder characterized by the presence of sickle-shaped red blood cells, leading to a range of clinical symptoms and complications. The clinical presentation of SCD can vary based on gender, with differences in the frequency, severity, and types of symptoms experienced by male and female patients.Males generally experience vaso-occlusive crises, which are acute episodes of severe pain, at a rate comparable to females but with varying intensity.[54] Males may experience fewer crises or less severe

pain, but this is not universal and can depend on individual disease severity and other factors. Pain management strategies for males often focus on opioid therapy, hydration, and supportive care. Males might have a more straightforward response to standard pain management protocols. A study found that males with SCD reported less severe pain during crises compared to females, potentially due to different pain perception and reporting mechanisms. Females with SCD often experience more frequent and severe vaso-occlusive crises compared to males.[55] This increased frequency is linked to hormonal fluctuations, such as those during menstruation, pregnancy, and menopause. Pain management for females may require more aggressive strategies, including higher doses of opioids, non-opioid analgesics, and additional supportive care measures. Research indicates that female patients experience more frequent and severe vaso-occlusive crises, which might be exacerbated by hormonal changes.Males are at significant risk for ACS, a severe lung complication associated with SCD.[56] Males might experience this complication more frequently due to a higher incidence of vaso-occlusive events leading to lung involvement. ACS management for males includes supportive care, antibiotics, and blood transfusions. Males may have a higher need for intensive care during ACS episodes. Studies have shown that males with SCD are at higher risk for developing ACS, which is related to the frequency of pain crises and other acute events.

Females with SCD also face the risk of ACS, but the severity may be influenced by hormonal factors and the presence of other coexisting conditions.[57] For females, ACS management may include similar strategies as for males but with additional considerations for potential hormonal influences and comorbidities. ACS is a major complication for both genders, but females might have different contributing factors such as hormonal changes or underlying infections.Males with SCD often experience chronic anemia due to the ongoing destruction of sickle cells.[58] The severity of anemia can vary but is generally managed through blood transfusions and medications. Males may receive regular blood transfusions and hydroxyurea treatment to manage anemia and prevent complications. Males with SCD often require regular blood transfusions to manage chronic anemia and prevent complications.Females with SCD might experience more severe anemia, which can be exacerbated by menstrual blood loss and pregnancy.[59] Anemia management for females might require additional interventions. Female patients may need adjusted transfusion schedules and iron chelation therapy to manage anemia and avoid complications such as iron overload. Females with SCD are at increased risk for severe anemia due to additional blood loss from menstruation and pregnancy.Males are at a higher risk for stroke compared to females with SCD. This increased risk is often due to the higher incidence of vaso-occlusive events and other risk factors. Stroke prevention for males includes regular transfusions, hydroxyurea, and other preventive measures. Males with SCD are more likely

to experience strokes, and management includes intensive preventive strategies.

Females also face stroke risks, though these might be lower compared to males. However, females may have unique risk factors such as hormonal changes during pregnancy or the use of oral contraceptives. Females need to be monitored for stroke risks, especially during pregnancy or when using hormonal contraceptives. While females have a lower incidence of stroke compared to males, factors such as pregnancy and oral contraceptive use can affect their risk. Priapism, a painful and persistent erection, is a common complication in males with SCD.[60] It requires urgent treatment to prevent long-term damage. Treatment for priapism includes hydration, medications, and sometimes surgical interventions. Priapism is a prevalent condition among males with SCD, requiring prompt medical attention. Priapism does not occur in females, as it is a condition specific to male physiology. Priapism is a male-specific condition and does not apply to female patients with SCD.

Males may experience chronic pain as a long-term complication of SCD.[61] This pain can be managed through a combination of medications and physical therapy. Males might be more prone to osteonecrosis, a condition where bone tissue dies due to loss of blood supply. Males with SCD may experience chronic pain and osteonecrosis, requiring long-term management strategies. Females with SCD also experience chronic pain, which may be more intense and frequent compared to males. Females are also at risk for osteonecrosis, and their management might involve both pharmacological and non-pharmacological treatments. Females with SCD may experience more frequent and severe chronic pain and are also at risk for osteonecrosis.Males with SCD may face complications related to fertility and sexual health, including priapism and reduced fertility.[62] Males with SCD might experience issues such as priapism and reduced fertility, which require specific medical attention. Females face reproductive health challenges related to pregnancy, menstrual irregularities, and potential impacts on fertility. Female patients with SCD experience unique reproductive health challenges, including risks during pregnancy and menstrual irregularities. Male children with SCD may experience growth delays or other developmental issues due to the chronic nature of the disease. Males with SCD might face growth delays and developmental issues that require careful monitoring. Female children with SCD may also face growth and development challenges, with potential delays in puberty and physical growth. Female children with SCD may experience delayed growth and puberty, which needs to be managed through regular check-ups and appropriate interventions.

Treatment Disparities and Gender-Specific Interventions

Sickle cell anemia (SCA) is a genetic disorder that significantly impacts the quality of life for those affected. While advancements in treatment have improved patient outcomes, disparities still exist in how therapies are administered and the effectiveness of these treatments for different genders. One of the most

noticeable disparities in the treatment of sickle cell anemia is the variation in how male and female patients respond to therapies. Hydroxyurea, a common treatment used to reduce the frequency of vaso-occlusive crises and other complications, has been shown to have different efficacy and side effects between genders. A study found that while hydroxyurea treatment led to a reduction in pain crises for both genders, female patients reported more frequent gastrointestinal side effects compared to males, suggesting a need for gender-specific dosing strategies.[63]Pain management in sickle cell anemia presents unique challenges for both males and females, but there are notable gender differences in pain perception and response to treatment.[64] Females with sickle cell anemia may experience more severe pain and may require different pain management strategies compared to males. Gender-specific approaches, such as adjusting opioid dosages or incorporating alternative pain management techniques, are essential for effectively addressing these differences. Research indicates that females with sickle cell anemia often experience more severe and frequent pain crises, which may necessitate tailored pain management strategies, including a combination of opioids and non-opioid therapies.

Blood transfusions are used in the management of sickle cell anemia to prevent and treat complications such as stroke and acute chest syndrome. There are gender-related disparities in the utilization and outcomes of blood transfusion therapies. For instance, males are more likely to receive blood transfusions due to a higher incidence of complications like priapism and stroke, while females might face barriers to accessing transfusions due to issues such as lower hemoglobin levels or hormonal influences. A study found that males with sickle cell anemia had higher rates of blood transfusions for acute complications, while females faced more challenges in accessing timely transfusions due to lower hemoglobin levels and other factors.Hydroxyurea is a cornerstone of sickle cell anemia treatment, but there is evidence that gender may influence how patients respond to this medication.[65] Females may require different dosing regimens compared to males, and there are calls for more research into gender-specific dosing strategies to ensure both efficacy and safety. Gender-specific considerations for dosing and monitoring can help optimize treatment outcomes for both male and female patients. Clinical trials have suggested that while hydroxyurea is effective for both genders, females might require different dosing strategies and closer monitoring for side effects compared to males.

Gender-based disparities also exist in the screening and preventive measures for sickle cell anemia.[66] Females may be less likely to receive regular screenings or preventive care due to socio-economic factors, health insurance coverage, or access to care. Implementing gender-specific screening programs and preventive measures can help bridge these gaps and ensure that all patients receive the necessary care. Studies show that females with sickle cell anemia may

have less frequent access to preventive care and screenings, highlighting the need for gender-specific outreach programs and improved healthcare access.Bone marrow transplantation (BMT) is a potential cure for sickle cell anemia, but there are gender differences in access to and outcomes of this treatment.[67] Males and females may have different success rates for BMT, influenced by factors such as disease severity, availability of suitable donors, and gender-based differences in healthcare access and support. Research indicates that while BMT can be a life-saving treatment for sickle cell anemia, females may face more challenges in finding suitable donors and may experience different outcomes compared to males.For female patients, the management of sickle cell anemia during pregnancy and other reproductive health issues is a critical aspect of treatment.[68] Pregnancy can complicate sickle cell anemia management, and there is gender-specific considerations for ensuring the health of both the mother and the fetus. Developing gender-specific guidelines for managing sickle cell anemia during pregnancy is essential for improving outcomes for female patients. A review of pregnancy outcomes in females with sickle cell anemia found that targeted prenatal care and management strategies are crucial for improving both maternal and fetal health outcomes.

The psychosocial needs of male and female patients with sickle cell anemia can differ, and providing gender-sensitive psychosocial support is an important aspect of comprehensive care.[69] Females may experience higher levels of psychological distress and may benefit from tailored counseling services that address their unique challenges related to disease management and personal well-being. Research has shown that females with sickle cell anemia may have higher levels of depression and anxiety, highlighting the need for gender-specific psychosocial support services.Educational interventions for sickle cell anemia patients can be tailored to address gender-specific needs.[70] For example, educational programs that focus on disease self-management, medication adherence, and lifestyle modifications can be designed to address the unique challenges faced by both male and female patients. Educational programs that address both disease management and lifestyle modifications can help patients develop effective self-management strategies, with considerations for gender-based differences in disease experience.Advocacy for gender equity in sickle cell anemia treatment involves addressing disparities in healthcare access, treatment quality, and support services.[31] Policy initiatives aimed at improving gender equity in sickle cell anemia care can help ensure that both male and female patients receive equitable treatment and support. Advocacy efforts focused on creating policies that promote gender equity in sickle cell anemia care are crucial for addressing disparities and ensuring fair treatment for all patients.

Treatment Responses and Adherence

In SCD, the effectiveness of treatments and the adherence to treatment regimens can differ between male and female patients.[72] Males generally respond to

hydroxyurea therapy with a reduction in the frequency of vaso-occlusive crises and an improvement in hemoglobin levels. However, the effectiveness can vary based on disease severity and other health factors. Males might have consistent adherence to hydroxyurea regimens due to fewer side effects or a better understanding of the treatment's benefits. Studies show that males with SCD often achieve favorable outcomes with hydroxyurea, with some experiencing side effects such as gastrointestinal discomfort.Females may experience different outcomes with hydroxyurea, including varying degrees of effectiveness and side effects. They may also have more severe side effects or require different dosing regimens. Adherence to hydroxyurea can be challenging for females due to side effects like nausea or concerns about long-term use, which may affect their commitment to the treatment regimen. Female patients might experience more severe side effects from hydroxyurea, which can affect their adherence to the treatment.Males may respond well to traditional pain management strategies, including opioids and non-opioid medications. However, their responses can be influenced by factors such as pain tolerance and access to care. Males might adhere to pain management regimens if they perceive them as effective and manageable, though misuse of opioids can be a concern. Males with SCD often follow prescribed pain management strategies effectively, though they may be at risk for opioid misuse.[73] Females may experience different pain responses and might require more aggressive pain management strategies. They might also have additional barriers to effective pain management. Females might struggle with adherence to pain management regimens due to side effects or a perception that the treatment is not effective. Females with SCD may have a higher level of pain and may experience more side effects from pain medications, affecting their adherence.

Males often receive blood transfusions for managing complications such as acute chest syndrome or stroke. They generally show positive responses to transfusion therapy. Males may adhere well to transfusion regimens as they are usually aware of the critical role of transfusions in managing acute complications. Males with SCD typically adhere to blood transfusion regimens due to their importance in managing acute complications.[74] Females also benefit from blood transfusions but may face additional challenges such as managing iron overload from frequent transfusions. Adherence can be influenced by logistical issues, such as scheduling transfusions around menstrual cycles or pregnancy-related concerns. Females might encounter barriers to regular blood transfusions, such as the need for careful management of iron levels.Males who undergo BMT may experience varying success rates based on factors like donor match and disease severity.[75] They often receive detailed pre-transplant evaluations and follow-ups. Males might be more compliant with pre- and post-transplant regimens due to clear treatment goals and the potential for a cure. Males undergoing BMT are often committed to the rigorous

pre- and post-transplant care protocols, which improves treatment success. Females may face unique challenges in BMT, such as finding suitable donors and managing post-transplant complications. Their treatment regimens might be more complex. Adherence can be impacted by factors such as hormonal changes or family responsibilities, which may affect their commitment to the BMT regimen. Female patients might face more challenges with BMT, including finding a suitable donor and managing post-transplant care. Males often receive standard doses of hydroxyurea, which are effective for managing SCD. Adherence is generally high if side effects are manageable. Adherence to hydroxyurea regimens can be influenced by the simplicity of the dosing schedule and the visible benefits of treatment.[75]

Males often adhere to hydroxyurea treatment schedules, benefiting from the medication's effects on SCD management.[76] Females might require adjusted dosing regimens due to different side effect profiles and responses to hydroxyurea. Adherence can be affected by concerns about long-term use, side effects, and the impact of the medication on menstrual cycles and pregnancy. Females might experience adherence issues with hydroxyurea due to side effects and concerns related to reproductive health. Males may adhere to pain management plans if they believe the treatments effectively alleviate their pain. However, adherence can be challenged by the long-term use of opioids and potential misuse. Males with SCD may have consistent adherence to pain management strategies, but issues with opioid misuse can arise. Females might face greater challenges with adherence to pain management due to severe pain and side effects of medications. They may also experience stigma related to pain management. Females might struggle with adherence to pain management regimens due to severe pain and medication side effects.Males are generally good at following preventive measures like vaccinations and regular check-ups. They often adhere well to recommendations aimed at preventing complications of SCD. Males with SCD typically follow preventive care recommendations effectively. Females might encounter barriers to adhering to preventive measures due to personal, economic, or systemic factors. Females might face barriers to preventive care, such as accessing healthcare services regularly. Males may have different psychosocial factors influencing adherence, such as support from family and social networks. They might be less likely to seek mental health support. Males might experience fewer psychosocial barriers to treatment adherence compared to females. Females might experience higher levels of psychological distress and face unique challenges related to treatment adherence, such as balancing care with family responsibilities. Females with SCD might face significant psychosocial challenges affecting their adherence to treatment regimens.Educational interventions for males can focus on the benefits of adherence and practical aspects of managing SCD. Males may respond well to straightforward educational materials.

Educational programs targeting males may focus on simplifying adherence to treatment regimens. Educational interventions for females may need to address more complex issues such as managing menstrual cycles, pregnancy, and long-term health concerns. Educational strategies for females may include information on managing specific health concerns and improving adherence.[76]

Health Inequities and Access to Care

SCD is a lifelong condition that requires ongoing medical care and management. However, the quality and accessibility of this care are not uniformly available to all individuals with SCD. Geographic location plays a critical role in determining access to healthcare services for individuals with SCD.[77] In urban areas, patients might have access to specialized sickle cell clinics and comprehensive care teams. However, those living in rural or underserved areas often face significant barriers to accessing these essential services. Socioeconomic status significantly affects access to SCD care.[78] Low-income patients may have limited access to healthcare resources due to financial constraints. Socioeconomic disparities contribute to unequal health outcomes by limiting access to medications, preventive care, and emergency services.Health insurance coverage is a major factor in accessing care for SCD patients.[79] Individuals with comprehensive insurance may receive regular medical care, whereas those with inadequate or no insurance face significant barriers. Inadequate insurance coverage often leads to delayed or fragmented care, which can exacerbate health issues.Cultural and linguistic barriers can significantly impact the quality of care for SCD patients. These barriers can result in misunderstandings about treatment plans and hinder the effectiveness of medical care. Additionally, cultural beliefs and practices may influence how patients perceive and manage their disease.Bias and discrimination among healthcare providers can negatively affect the care of SCD patients. Discriminatory attitudes or assumptions about SCD patients can lead to unequal treatment and lower quality of care. This bias can result in inadequate pain management and a lack of trust between patients and providers.Access to preventive care and regular screenings is crucial for managing SCD effectively. Preventive measures such as vaccinations, routine check-ups, and early detection of complications can significantly improve patient outcomes. Barriers to preventive care can lead to missed opportunities for early intervention and better disease management.Education and awareness about SCD are essential for effective disease management and patient advocacy. Low levels of awareness among patients and the general public can hinder efforts to address SCD-related health inequities. Increasing awareness and providing educational materials are vital for empowering patients and improving care.[76] Healthcare policies play a significant role in shaping the availability and quality of care for SCD patients. Policies that support comprehensive SCD care can improve patient outcomes, while those that are inadequate or poorly implemented can exacerbate health inequities. Effective healthcare policies

can help address gaps in care and ensure equitable access to necessary services.Community support plays a crucial role in filling gaps in SCD care. Support groups, non-profit organizations, and community health initiatives can provide resources, emotional support, and advocacy for patients. Community resources can help bridge gaps in care and offer additional support to patients.

Future Directions and Research Priorities

SCD is a complex and multifaceted condition that continues to pose significant challenges in clinical care, patient management, and research. While advancements have been made in understanding and treating SCD, there remains a pressing need for ongoing research and innovation.

1. Advancements in Gene Therapy and Genetic Research

Gene therapy represents a promising frontier in the treatment of SCD. Recent breakthroughs in gene editing technologies, such as CRISPR-Cas9, offer the potential to correct the genetic mutations responsible for SCD.[80] Research efforts are increasingly focused on refining these technologies to ensure safety, efficacy, and long-term success. Future studies will need to address questions related to the best methods for gene editing, potential off-target effects, and the long-term impact of genetic modifications.

2. Development of Novel Pharmacological Therapies

Despite the availability of treatments like hydroxyurea and new agents such as voxelotor and crizanlizumab, there is a continued need for the development of novel pharmacological therapies for SCD.[81] Future research should focus on discovering new drug candidates that target various aspects of the disease, including pain management, prevention of vaso-occlusive crises, and mitigation of organ damage. Identifying novel therapeutic targets and developing new medications will be crucial for advancing SCD care.

3. Enhancing Pain Management Strategies

Effective pain management remains a significant challenge for SCD patients.[82] Research should explore innovative approaches to pain management, including non-opioid therapies, alternative medicine, and psychological interventions. Investigating the underlying mechanisms of SCD-related pain and developing multimodal pain management strategies will be essential for improving patient outcomes and quality of life.

4. Addressing Health Disparities and Inequities

Health disparities in SCD care are a significant issue, with differences in access to care, treatment quality, and health outcomes based on socioeconomic factors, geographic location, and insurance coverage.[83] Future research should aim to identify and address these disparities through targeted interventions, policy changes, and community outreach programs. Understanding the root causes of health inequities and developing strategies to overcome them will be key to achieving more equitable care for all SCD patients.

5. Improving Patient Education and Self-Management

Patient education is crucial for effective disease management in SCD. Future research should explore methods for improving patient education and self-management strategies. This includes developing educational resources, enhancing health literacy, and creating tools to help patients manage their disease more effectively. Understanding the most effective ways to engage patients in their own care and promote adherence to treatment regimens will be vital.

6. Exploring Psychosocial Support Mechanisms

Addressing the psychosocial aspects of SCD is essential for holistic patient care. Research should focus on developing and evaluating interventions that provide psychological support, address mental health issues, and improve overall well-being for SCD patients and their families. This includes exploring the effectiveness of counseling, support groups, and mental health services.

7. Investigating the Long-Term Outcomes of SCD Treatments

Long-term outcomes of SCD treatments, including the effects of current therapies and new interventions, require ongoing investigation. Research should focus on the long-term efficacy and safety of treatments, including gene therapies and novel medications. Understanding the long-term impacts of treatments will help guide future therapeutic approaches and improve patient management strategies.

8. Strengthening SCD Research Networks and Collaboration

Strengthening research networks and fostering collaboration among researchers, clinicians, and patients is crucial for advancing SCD research. Future efforts should focus on building collaborative research initiatives, sharing data and resources, and creating platforms for interdisciplinary research. Collaborative approaches can accelerate discoveries and enhance the development of new therapies and interventions.

9. Expanding Global Research Initiatives

SCD is a global health issue, and expanding research initiatives beyond high-income countries is essential. Future research should focus on addressing the unique challenges faced by patients in low- and middle-income countries, including access to care, treatment availability, and disease management. Expanding global research efforts will contribute to a more comprehensive understanding of SCD and support international efforts to combat the disease.

10. Utilizing Advanced Technologies in SCD Research

Advanced technologies, such as big data analytics, artificial intelligence, and personalized medicine, offer new opportunities for SCD research. Future studies should explore how these technologies can be used to better understand the disease, predict outcomes, and develop personalized treatment plans. Harnessing these technologies will enable researchers to make data-driven decisions and advance the field of SCD research.

Conclusion

SCD is a multifaceted condition that affects millions of people worldwide, presenting a unique set of challenges and opportunities for research and clinical care. Over the years, significant advancements have been made in

understanding the pathophysiology of SCD, developing treatments, and improving patient care. However, there remains a pressing need to address ongoing issues and explore new avenues for enhancing the lives of individuals living with SCD. SCD is a genetic disorder characterized by the production of abnormal hemoglobin, leading to distorted red blood cells that cause a range of complications including pain crises, organ damage, and increased risk of infections. Advances in medical research have led to the development of various therapeutic strategies, including hydroxyurea, novel medications like voxelotor and crizanlizumab, and innovative approaches such as gene therapy. These treatments have improved disease management and patient outcomes, yet challenges persist in achieving optimal care for all patients.Despite progress, there are significant disparities in SCD care that need to be addressed. Geographic and socioeconomic barriers limit access to specialized care for many individuals, particularly those in rural or low-income settings. Disparities in health insurance coverage and the effects of provider bias further contribute to unequal treatment outcomes. Additionally, psychosocial factors, including mental health issues and inadequate patient education, play a critical role in managing the disease effectively.

References

1. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nature reviews Disease primers. 2018;4(1):1-22.
2. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine (Baltimore). 2024 ;103(2): e36898. doi: 10.1097/MD.0000000000036898. PMID: 38215146; PMCID: PMC10783340.
3. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates. Ann Med Surg (Lond). 2024;86(3):1570-1574. doi: 10.1097/MS9.0000000000001763. PMID: 38463100; PMCID: PMC10923353.
4. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: Prevalence, impact, and interventions: A Review. Medicine (Baltimore). 2024;103(20): e38164. doi: 10.1097/MD.0000000000038164. PMID: 38758879; PMCID: PMC11098235.
5. Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. The Scientific World Journal. 2012;2012(1):949535.
6. Obeagu EI, Obeagu GU. Management of diabetes mellitus patients with sickle cell anemia: Challenges and therapeutic approaches. Medicine (Baltimore). 2024 Apr 26;103(17): e37941. doi: 10.1097/MD.0000000000037941. PMID: 38669382; PMCID: PMC11049766.
7. Darbari DS, Sheehan VA, Ballas SK. The vaso- occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. European journal of haematology. 2020;105(3):237-246.

8. Nazroo JY, Edwards AC, Brown GW. Gender differences in the onset of depression following a shared life event: a study of couples. Psychological medicine. 1997;27(1):9-19.
9. Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. British journal of anaesthesia. 2013;111(1):52-58.
10. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine (Baltimore). 2023;102(48): e36462. doi: 10.1097/MD.0000000000036462. PMID: 38050205; PMCID: PMC10695528.
11. Dilli PP, Obeagu E, Tamale A, Ajugwo A, Pius T, Makeri D. Update on the practice of premarital screening for sickle cell traits in Africa: a systematic review and meta-analysis. BMC Public Health. 2024;24(1):1467. doi: 10.1186/s12889-024-19001-y. PMID: 38822327; PMCID: PMC11143629.
12. Barton-Gooden A, Grindley M, Knight-Madden J, Asnani M. Gender influences on the health of adolescents with sickle cell disease. Psychology, Health & Medicine. 2019;24(4):470-480.
13. Smiley D, Dagogo-Jack S, Umpierrez G. Therapy insight: metabolic and endocrine disorders in sickle cell disease. Nature Clinical Practice Endocrinology & Metabolism. 2008;4(2):102-109.
14. Reek S. Gender differences in cardiac interventions. Cardiovascular Medicine. 2019;22(02).
15. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: Diarrhea in sickle cell anemia. Medicine (Baltimore). 2024;103(18): e38075. doi: 10.1097/MD.0000000000038075. PMID: 38701274; PMCID: PMC11062666.
16. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine (Baltimore). 2024;103(6): e37127. doi: 10.1097/MD.0000000000037127. PMID: 38335412; PMCID: PMC10860944.
17. Obeagu EI. Eosinophilic dialogues: A molecular exploration of sickle cell anemia severity. Annals of Medicine and Surgery. 2024:10-97.
18. Williams TN. Sickle cell disease in sub-Saharan Africa. Hematology/Oncology Clinics. 2016;30(2):343-358.
19. Darbari DS, Sheehan VA, Ballas SK. The vaso- occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. European journal of haematology. 2020;105(3):237-246.
20. Zakaria O, Buhalim RA, Almulhim F, Al Jabr FA, Alrashid A, Almutairi M. Clinical and laboratory predictors of painful vaso-occlusive crisis among sickle cell disease patients: A single-center study in Saudi Arabia. Cureus. 2021;13(5).
21. Helvaci MR, Acipayam C, Aydogan A, Akkucuk S, Oruc C, Gokce C. Acute chest syndrome in severity of sickle cell diseases. International Journal of Clinical and Experimental Medicine. 2014;7(12):5790.
22. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Hormones and behavior. 2012;62(3):263-271.
23. Dampier C, LeBeau P, Rhee S, Lieff S, Kesler K, Ballas S, Rogers Z, Wang W, Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) Site Investigators. Health-related quality of life

in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. American journal of hematology. 2011;86(2):203.
24. Ahmed AE, Alaskar S, McClish DK, Ali YZ, Al-Suliman AM. Gender Differences in Health-Related Quality of Life: A Survey of Saudis with SCD. J Womens Health, Issues Care 5. 2016; 1:2.
25. Linton EA, Goodin DA, Hankins JS, Kanter J, Preiss L, Simon J, Souffront K, Tanabe P, Gibson R, Hsu LL, King A. A survey-based needs assessment of barriers to optimal sickle cell disease care in the emergency department. Annals of emergency medicine. 2020;76(3): S64-72.
26. Ceovic R, Mance M, BukvicMokos Z, Svetec M, Kostovic K, StulhoferBuzina D. Psoriasis: female skin changes in various hormonal stages throughout life—puberty, pregnancy, and menopause. BioMed research international. 2013;2013(1):571912.
27. Ceglie G, Di Mauro M, Tarissi De Jacobis I, De Gennaro F, Quaranta M, Baronci C, Villani A, Palumbo G. Gender-related differences in sickle cell disease in a pediatric cohort: a single-center retrospective study. Frontiers in Molecular Biosciences. 2019; 6:140.
28. Ramsay Z, Bartlett R, Ali A, Grant J, Gordon-Strachan G, Asnani M. Sickle cell disease and pain: is it all vaso-occlusive crises? The Clinical Journal of Pain. 2021;37(8):583-590.
29. Sharma D, Day ME, Stimpson SJ, Rodeghier M, Ghafuri D, Callaghan M, Zaidi AU, Hannan B, Kassim A, Zempsky W, Wellons M. Acute vaso-occlusive pain is temporally associated with the onset of menstruation in women with sickle cell disease. Journal of Women's Health. 2019;28(2):162-169.
30. Glezerman M, Ciechanover A, Legato MJ. A critical view of the revolution of precision medicine: genetics, epigenetics, sex, and gender. In Sex, Gender, and Epigenetics 2023: 9-25. Academic Press.
31. Abd El-Kader SM, Al-Shreef FM. Impact of aerobic exercises on selected inflammatory markers and immune system response among patients with sickle cell anemia in asymptomatic steady state. African Health Sciences. 2018;18(1):111-119.
32. Darghouth D, Koehl B, Madalinski G, Heilier JF, Bovee P, Xu Y, Olivier MF, Bartolucci P, Benkerrou M, Pissard S, Colin Y. Pathophysiology of sickle cell disease is mirrored by the red blood cell metabolome. Blood, The Journal of the American Society of Hematology. 2011;117(6): e57-66.
33. Ceglie G, Di Mauro M, Tarissi De Jacobis I, De Gennaro F, Quaranta M, Baronci C, Villani A, Palumbo G. Gender-related differences in sickle cell disease in a pediatric cohort: a single-center retrospective study. Frontiers in Molecular Biosciences. 2019; 6:140.
34. Zhou Y, Liu S, Wang X, Fu Y, Su F, Cao L, Zha X, Wen Y. Implications of gender-based variabilities in bone mineral density and hemoglobin levels. BMC musculoskeletal disorders. 2021; 22:1-7.
35. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129-151.
36. Smith-Whitley K. Reproductive issues in sickle cell disease. Hematology 2014, the American Society of Hematology Education Program Book. 2014;2014(1):418-424.

37. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):2244-52.
38. De D, Thakur I. Assessing and managing people with sickle cell disease presenting with vaso-occlusive crisis in the emergency department. Emergency Nurse. 2024;32(1).
39. Ugwu AO. Gender differences in the complications of sickle cell Anemia. International Journal of Medicine and Health Development. 2022;27(1):38-42.
40. Bhasin N, Sarode R. Acute chest syndrome in Sickle Cell Disease. Transfusion Medicine Reviews. 2023:150755.
41. Kawamoto KR, Davis MB, Duvernoy CS. Acute coronary syndromes: differences in men and women. Current atherosclerosis reports. 2016; 18:1-10.
42. Sahu M, Biswas AK, Uma K. Detection of Sickle cell anemia in red blood cell. International Journal of Engineering and Applied Sciences (IJEAS). 2015;2(3):45-48.
43. Mazzucco S, Li L, Tuna MA, Rothwell PM. Age-specific sex-differences in cerebral blood flow velocity in relation to haemoglobin levels. European Stroke Journal. 2024:23969873241245631.
44. Fowler Jr JE, Koshy M, Strub M, Chinn SK. Priapism associated with the sickle cell hemoglobinopathies: prevalence, natural history and sequelae. The Journal of urology. 1991;145(1):65-68.
45. Hughes M. Rheumatic manifestations of haemoglobinopathies. Current Rheumatology Reports. 2018; 20:1-9.
46. Daltro G, Franco BA, Faleiro TB, Rosário DA, Daltro PB, Fortuna V. Osteonecrosis in sickle cell disease patients from Bahia, Brazil: a cross-sectional study. International Orthopaedics. 2018; 42:1527-1534.
47. Smith-Whitley K. Reproductive issues in sickle cell disease. Hematology 2014, the American Society of Hematology Education Program Book. 2014;2014(1):418-424.
48. Alagbe EE, Susu AA, Dosunmu AO. Sickle cell disease (SCD) management: A Theoretical Review. International Journal of Research and Reviews in Applied Sciences. 2013;16(3):483-500.
49. Mitchell MJ, Carpenter GJ, Crosby LE, Bishop CT, Hines J, Noll J. Growth status in children and adolescents with sickle cell disease. Pediatric hematology and oncology. 2009;26(4):202-215.
50. Benton TD, Ifeagwu JA, Smith-Whitley K. Anxiety and depression in children and adolescents with sickle cell disease. Current psychiatry reports. 2007;9(2):114-121.
51. Overholser LS, Diers T, Hassell K. Sickle Cell Disease. Care of Adults with Chronic Childhood Conditions: A Practical Guide. 2016:245-258.
52. Jonassaint CR, Beach MC, Haythornthwaite JA, Bediako SM, Diener-West M, Strouse JJ, Lanzkron S, Onojobi G, Carroll CP, Haywood C. The association between educational attainment and patterns of emergency department utilization among adults with sickle cell disease. International journal of behavioral medicine. 2016; 23:300-309.
53. Munung NS, Treadwell M, Kamga KK, Dennis-Antwi J, Anie K, Bukini D, Makani J, Wonkam A. Caught between pity, explicit bias, and discrimination: a qualitative study on the impact of stigma on the quality of life of persons living with sickle cell disease in three African countries. Quality of Life Research. 2024;33(2):423-432.

54. Nottage KA, Hankins JS, Faughnan LG, James DM, Richardson J, Christensen R, Kang G, Smeltzer M, Cancio MI, Wang WC, Anghelescu DL. Addressing challenges of clinical trials in acute pain: the Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study. Clinical Trials. 2016;13(4):409-416.
55. Shah N, Bhor M, Xie L, Arcona S, Halloway R, Paulose J, Yuce H. Evaluation of vaso-occlusive crises in United States sickle cell disease patients: a retrospective claims-based study. Journal of Health Economics and Outcomes Research. 2019;6(3):106.
56. Klings ES, Steinberg MH. Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management. Expert Review of Hematology. 2022;15(2):117-125.
57. De Sanctis V, Soliman AT, Daar S, Canatan D, Di Maio S, Kattamis C. Current issues and options for hormonal contraception in adolescents and young adult women with sickle cell disease: an update for health care professionals. Mediterranean journal of hematology and infectious diseases. 2020;12(1).
58. Alrayyes S, Baghdan D, Haddad RY, Compton AA, Mohama S, Goreishi R, Kawar N. Sickle cell disease; An overview of the disease and its systemic effects. Disease-a-Month. 2018;64(6):283-289.
59. Stimpson SJ, Rebele EC, DeBaun MR. Common gynecological challenges in adolescents with sickle cell disease. Expert Review of Hematology. 2016;9(2):187-196.
60. Idris IM, Burnett AL, DeBaun MR. Epidemiology and treatment of priapism in sickle cell disease. Hematology. 2022;2022(1):450-458.
61. Matthie N, Ross D, Sinha C, Khemani K, Bakshi N, Krishnamurti L. A qualitative study of chronic pain and self-management in adults with sickle cell disease. Journal of the National Medical Association. 2019;111(2):158-168.
62. Al-Marhoon MS. Demography of priapism: Comparison between sickle cell and non-sickle cell disease patients. ARC Journal of Urology. 2021;3(1).
63. Hejazi RA, Mandourah NA, Alsulami AS, Bakhsh HT, Diri RM, Noor AO. Commonly used agent for acute pain management of sickle cell anemia in Saudi Emergency Department: A narrative review. Saudi Pharmaceutical Journal. 2021;29(6):487-496.
64. Edwards CL, Scales MT, Loughlin C, Bennett GG, Harris-Peterson S, Castro LM, Whitworth E, Abrams M, Feliu M, Johnson S, Wood M. A brief review of the pathophysiology, associated pain, and psychosocial issues in sickle cell disease. International journal of behavioral medicine. 2005; 12:171-179.
65. Ahmed S, Ibrahim U. The Roles of Acute and Chronic Marrow Dysfunctions in the Aetiology of Anaemia in Sickle Cell Disease: Pathogenesis and Management: Marrow dysfunction in SCD. Orient Journal of Medicine. 2024;36(3-4).
66. Barton-Gooden A, Grindley M, Knight-Madden J, Asnani M. Gender influences on the health of adolescents with sickle cell disease. Psychology, Health & Medicine. 2019;24(4):470-480.
67. Aslam HM, Yousuf S, Kassim A, Iqbal SM, Hashmi SK. Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availibility. Bone Marrow Transplantation. 2018;53(11):1390-1400.

68. Boga C, Ozdogu H. Pregnancy and sickle cell disease: a review of the current literature. Critical reviews in oncology/hematology. 2016; 98:364-374.
69. Tseng HH, Nkimbeng M, Han HR. Gender differences in psychosocial characteristics and diabetes self- management among inner- city African Americans. Nursing Open. 2022;9(5):2425-2433.
70. Wilkie DJ, Telisnor G, Powell-Roach K, Rangel AP, Greenlee AL, Ezenwa MO, Gallo AM, Black LV, Gomes de Siqueira A, Dyal BW, Kalyanaraman S. CHOICES for sickle cell reproductive health: A protocol of a randomized preconception intervention model for a single gene disorder. Plos one. 2023;18(12):e0294907.
71. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP. Men's Essential roles in the Management of Sickle Cell Anemia. Newport International Journal of Scientific and Experimental Sciences. 2023;4(2):20-29.
72. Adams-Graves P, Bronte-Jordan L. Recent treatment guidelines for managing adult patients with sickle cell disease: challenges in access to care, social issues, and adherence. Expert review of hematology. 2016;9(6):541-552.
73. Sinha CB, Bakshi N, Ross D, Krishnamurti L. Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: a qualitative study. JAMA network open. 2019;2(5):e194410-.
74. Wanko SO, Telen MJ. Transfusion management in sickle cell disease. Hematology/Oncology Clinics. 2005;19(5):803-826.
75. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, Hegland J, Kamani N, Kernan NA, King R, Ratanatharathorn V. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood, The Journal of the American Society of Hematology. 2001;98(7):2043-2051.
76. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatric blood & cancer. 2012;59(2):365-371.
77. Khan H, Krull M, Hankins JS, Wang WC, Porter JS. Sickle cell disease and social determinants of health: a scoping review. Pediatric blood & cancer. 2023;70(2):e30089.
78. Wahab S, Kelly K, Klingler M, Pirovic A, Futch K, Rennie C, Durham D, Herber D, Gramling G, Price S, Costin JM. Impact of Race, Socioeconomic Status, and Geography on Healthcare Outcomes for Children with Sickle Cell Disease in the United States: A Scoping Review. Cureus. 2024;16(3).
79. Kauf TL, Coates TD, Huazhi L, Mody- Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. American journal of hematology. 2009;84(6):323-327.
80. Ma L, Yang S, Peng Q, Zhang J, Zhang J. CRISPR/Cas9-based gene-editing technology for sickle cell disease. Gene. 2023; 874:147480.
81. Leibovitch JN, Tambe AV, Cimpeanu E, Poplawska M, Jafri F, Dutta D, Lim SH. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope? Blood Reviews. 2022; 53:100925.
82. Lakkakula BV, Sahoo R, Verma H, Lakkakula S. Pain management issues as

part of the comprehensive care of patients with sickle cell disease. Pain Management Nursing. 2018;19(6):558-572.
83. Lee L, Smith-Whitley K, Banks S, Puckrein G. Reducing health care disparities in sickle cell disease: a review. Public Health Reports. 2019;134(6):599-607.